ACUR Financial Facts
Total operating expenses: 2.29MResearch and development: 841K
See Full Income Statement
Cash and cash equivalents: 4.27M
Prepaid expenses and other current assets: 411K
See Full Balance Sheet
Acura Pharmaceuticals, Inc. (ACUR) Earnings
|
Expand Research on ACUR
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -73.7% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -5.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/18/24 |
Q324 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 11/11/24 |
Q324 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/26/24 | Q224 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/20/24 | Q224 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 5/27/24 | Q124 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 5/21/24 | Q124 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 2/28/24 | Q423 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 11/13/23 | Q323 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |


